Research Projects Page

Since our inception as an outcome committee in 2015, we have consistently and considerably expanded our ability to produce rigorous outcomes research. In 2018, we established a more formal program and leadership, including full time outcomes research staff. The result of these allocated resources has been a productive output across multiple specialty disease states. Below are highlighted outcomes from studies completed in recent years.

Research Project List

Filter
Research categories (field_research_categories)
Filter
Research categories (field_research_categories)
91-100 of 128 results

Primary Prevention of Venous Thromboembolism with Apixaban for Multiple Myeloma Patients Receiving Immunomodulatory Agents

Immunomodulatory therapies for multiple myeloma can increase patient risk for venous thromboembolism (VTE). This phase IV single-arm study assessed the rate of symptomatic VTE over 6 months in 50 patients with multiple myeloma receiving immunomodulatory therapy and apixaban for primary prevention. No patients experienced symptomatic VTE or a major hemorrhage and 3 patients experienced clinically relevant non-major hemorrhage but were able to resume apixaban after medical management.

Development of a Quality Measures Tool for the Utilization of Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Integrated Specialty Pharmacy Initiative

The purpose of this initiative was to develop a tool to assess quality in the use of TKIs to manage NSCLC and ultimately track variables such as proper medication use, patient safety and healthcare resource utilization.

Risk Factors for Non-Adherence to Self-Injectable Biologic Therapy in Inflammatory Bowel Disease: A Validation Cohort Study

The purpose of this study was to validate prior findings of risk factors for non-adherence to biologic therapy for adult inflammatory bowel disease: narcotic use, psychiatric diagnosis history, prior biologic use, and smoking. This study found that previously identified cumulative risk factors remain significant.

Risk Factors for Non-Adherence to Biologic Therapy in Adult Patients with Inflammatory Bowel Disease (IBD): A Retrospective Analysis

This study assessed medication non-adherence (defined as medication possession ratio (MPR)

Expanding Heart Transplant in the Era of Direct-Acting Antiviral Therapy for Hepatitis C

The objective of this study was to better define the association of hepatitis C-positive donors with heart transplant volumes, wait-list duration, and mortality at 1 year. Findings suggest that infection is well-tolerated and curable in heart transplant recipients with donor-derived hepatitis C, and 1-year survival is equivalent to that in recipients of hepatitis C-negative donors.

Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia

This study looked at 21 acute myeloid leukemia patients who had received a hematopoietic cell transplant and experienced relapsed disease. Each patient underwent salvage therapy with a venetoclax- based treatment regimen. Nineteen patients were assessed for treatment response and 12 of the 19 patients responded to venetoclax-based salvage therapy, leading to a 63.2% response rate.

Closing the Gap: Identifying Rates and Reasons for Nonadherence in a Specialty Population

This study evaluated reasons for nonadherence in a random 10% sample of the patients identified as nonadherent (PDC less than 80%) from the study below. We found that 40% of patients classified as nonadherent were misclassified, with 31% of those due to external fills, and 60% due to provider-recommended gaps in therapy. Most cases of true nonadherence were due to an inability to reach the patient.

Pharmacologic Management of HCV Treatment in Patients with HCV Monoinfection vs. HIV/HCV Coinfection: Does Coinfection Really Matter?

In this ambispective cohort study of patients referred to an outpatient Infectious Diseases Clinic for chronic HCV, we found significant differences in patient demographics, drug interactions, and time to treat between HCV monoinfected and HIV/HCV coinfected patients. This study provides a broad, yet concise overview of the differences in caring for patients with and without HIV/HCV coinfection.

Navigating the Wild West of Medication Adherence Reporting in Specialty Pharmacy

This article highlights the challenges in standardizing adherence methodologies as well as the key elements to consider when interpreting adherence results. Specialty pharmacies should consider using adherence measures to identify and intervene on non-adherence patients. In addition, integrated specialty pharmacies should work to link adherence to clinical outcomes and healthcare cost savings.

Healthcare Provider Attitudes and Knowledge Around Pre-Exposure Prophylaxis (PrEP) for the Prevention of HIV-Infection in Tennessee

In the Southern US, HIV prevalence is disproportionately high and PrEP use is disproportionately low. This cross-sectional survey study assessed Tennessee primary care providers’ current PrEP knowledge, attitudes, and prescribing practices with the aim to determine barriers to PrEP provision specific to TN providers.